Re: This is one sick puppy
Hey Ulingt, You sounded like you are sympathetic to the Bevyxxa mistakes that the BOD made. Notice that I didn't blame this mistake on SG. Those BOD, especially Hollings Renton and Jeffrey Bird have been there for a long time. Most of the BOD have MBAs and are business people as well. Therefore, they should know that the number one job of management and the board is to enhance the shareholder's value. I have been holding this stock for over 2 and a half years and I am still in negative. Can you tell me why? What do you want to say to those shareholders who brought shares between $48 to $55 in the last 3 years? You want them to just sell and leave silently? I know eventually, this company will be sold and the only question is when and how much. What gets me is that they should know better after the Bevyxxa debacle. As the late George Rathmann of Amgen had said many times that no biotech company can sustain a global marketing team with only 1 billion $ product. Knowing that Bevyxxa was a failure, what do they have in the pipeline that will come online in the next year or two? Nothing! Therefore, how come they didn't explore licensing deal at the minimum. Why is it The Medicine company sold before their billion $ product being approved? Why did Kite Pharma sold to Gilead before its product being approved? I hope you are here is for your investment returns and not for the interest of science. When you see the management is not advocating enhancing shareholder's value; you as the shareholder have the responsibility to speak up and this is exactly what I am doing here.